<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36167892</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>29</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Sep</Month><Day>27</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>High-throughput analysis of anti-poliovirus neutralization antibody titre in human serum by the pseudovirus neutralization test.</ArticleTitle><Pagination><StartPage>16074</StartPage><MedlinePgn>16074</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">16074</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-022-20544-6</ELocationID><Abstract><AbstractText>To monitor vulnerability of countries to poliovirus (PV) outbreaks, serosurveillance of anti-PV neutralization antibody is conducted by conventional PV neutralization test (cPNT), which uses live PV strains. We previously developed a pseudovirus PV neutralization test (pPNT) as an alternative to cPNT, which uses PV pseudovirus that expresses luciferase as a reporter in the infection without producing infectious PV. In the present study, we established a high-throughput pPNT (HTpPNT) for a large-scale serosurveillance. The HTpPNT system was evaluated with 600 human serum samples obtained from a broad range of age groups of healthy volunteers (ages of 0-89&#xa0;years). HTpPNT showed high correlation with cPNT (R<sup>2</sup> for anti-type 1, 2, and 3 PV neutralization antibody titres are 0.90, 0.84, and 0.90, respectively). By using HTpPNT, we analyzed relative neutralizing antibody titre of the sera against a type 1 PV wild-type strain (Mahoney strain) to that against the type 1 Sabin strain. As a result, a correlation between the age (&#x2265;&#x2009;60&#xa0;years) and the relative neutralizing antibody titre was observed (n&#x2009;=&#x2009;15-16, P&#x2009;=&#x2009;0.0000023-0.041), while the types of PV vaccine (i.e., oral PV vaccine and Sabin strain-based IPV) had no effect. HTpPNT would serve as a useful alternative to cPNT in a large-scale serosurveillance.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Arita</LastName><ForeName>Minetaro</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Virology II, National Institute of Infectious Diseases, 4-7-1 Gakuen, Musashimurayama-shi, Tokyo, 208-0011, Japan. minetaro@nih.go.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iwai-Itamochi</LastName><ForeName>Masae</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Virology, Toyama Institute of Health, 17-1 Nakataikoyama, Imizu-shi, Toyama, 939-0363, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.13.12.-</RegistryNumber><NameOfSubstance UI="D008156">Luciferases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008156" MajorTopicYN="N">Luciferases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>7</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>9</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>28</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>9</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36167892</ArticleId><ArticleId IdType="pmc">PMC9514167</ArticleId><ArticleId IdType="doi">10.1038/s41598-022-20544-6</ArticleId><ArticleId IdType="pii">10.1038/s41598-022-20544-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Shimizu H. Development and introduction of inactivated poliovirus vaccines derived from Sabin strains in Japan. Vaccine. 2016;34:1975&#x2013;1985. doi: 10.1016/j.vaccine.2014.11.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2014.11.015</ArticleId><ArticleId IdType="pubmed">25448090</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwai M, et al. Evaluation of a two-dose administration of live oral poliovirus vaccine for wild and virulent vaccine-derived poliovirus type 1, 2, 3 strains in Japan. Scand. J. Infect. Dis. 2008;40:247&#x2013;253. doi: 10.1080/00365540701596003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00365540701596003</ArticleId><ArticleId IdType="pubmed">17907043</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO. http://www.polioeradication.org/Portals/0/Document/Resources/PostEradication/GAPIII_2014.pdf.</Citation></Reference><Reference><Citation>WHO. https://polioeradication.org/wp-content/uploads/2022/07/WHO-Global-Action-Plan-for-Poliovirus-Containment-GAPIV.pdf.</Citation></Reference><Reference><Citation>WHO. https://polioeradication.org/polio-today/polio-now/this-week/circulating-vaccine-derived-poliovirus/.</Citation></Reference><Reference><Citation>Arita M, Iwai M, Wakita T, Shimizu H. Development of a poliovirus neutralization test with poliovirus pseudovirus for measurement of neutralizing antibody titer in human serum. Clin. Vaccine Immunol. 2011;18:1889&#x2013;1894. doi: 10.1128/CVI.05225-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CVI.05225-11</ArticleId><ArticleId IdType="pmc">PMC3209023</ArticleId><ArticleId IdType="pubmed">21880850</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S, et al. A safe and reliable neutralization assay based on pseudovirus to measure neutralizing antibody titer against poliovirus. J. Med. Virol. 2017;89:2075&#x2013;2083. doi: 10.1002/jmv.24909.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.24909</ArticleId><ArticleId IdType="pubmed">28786502</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Z, et al. A simple and safe antibody neutralization assay based on polio pseudoviruses. Hum. Vaccines Immunother. 2019;15:349&#x2013;357. doi: 10.1080/21645515.2018.1526553.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2018.1526553</ArticleId><ArticleId IdType="pmc">PMC6422504</ArticleId><ArticleId IdType="pubmed">30273512</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M, Iwai-Itamochi M. Evaluation of antigenic differences between wild and Sabin vaccine strains of poliovirus using the pseudovirus neutralization test. Sci. Rep. 2019;9:11970. doi: 10.1038/s41598-019-48534-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-48534-1</ArticleId><ArticleId IdType="pmc">PMC6700111</ArticleId><ArticleId IdType="pubmed">31427704</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S, et al. Comparison of the neutralizing activities of antibodies in clinical sera against both Sabin and wild-type polio pseudoviruses. J. Virol. Methods. 2022;300:114376. doi: 10.1016/j.jviromet.2021.114376.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2021.114376</ArticleId><ArticleId IdType="pubmed">34826519</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M, Nagata N, Sata T, Miyamura T, Shimizu H. Quantitative analysis of poliomyelitis-like paralysis in mice induced by a poliovirus replicon. J. Gen. Virol. 2006;87:3317&#x2013;3327. doi: 10.1099/vir.0.82172-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.82172-0</ArticleId><ArticleId IdType="pubmed">17030866</ArticleId></ArticleIdList></Reference><Reference><Citation>Rimoin AW, et al. Ebola virus neutralizing antibodies detectable in survivors of Theyambuku, Zaire outbreak 40 years after infection. J. Infect. Dis. 2018;217:223&#x2013;231. doi: 10.1093/infdis/jix584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jix584</ArticleId><ArticleId IdType="pmc">PMC5853670</ArticleId><ArticleId IdType="pubmed">29253164</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukushi S, et al. Evaluation of a novel vesicular stomatitis virus pseudotype-based assay for detection of neutralizing antibody responses to SARS-CoV. J. Med. Virol. 2006;78:1509&#x2013;1512. doi: 10.1002/jmv.20732.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.20732</ArticleId><ArticleId IdType="pmc">PMC7166816</ArticleId><ArticleId IdType="pubmed">17063504</ArticleId></ArticleIdList></Reference><Reference><Citation>Han DP, Kim HG, Kim YB, Poon LL, Cho MW. Development of a safe neutralization assay for SARS-CoV and characterization of S-glycoprotein. Virology. 2004;326:140&#x2013;149. doi: 10.1016/j.virol.2004.05.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2004.05.017</ArticleId><ArticleId IdType="pmc">PMC7127165</ArticleId><ArticleId IdType="pubmed">15262502</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright E, et al. Investigating antibody neutralization of lyssaviruses using lentiviral pseudotypes: A cross-species comparison. J. Gen. Virol. 2008;89:2204&#x2013;2213. doi: 10.1099/vir.0.2008/000349-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.2008/000349-0</ArticleId><ArticleId IdType="pmc">PMC2886951</ArticleId><ArticleId IdType="pubmed">18753230</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamin A, et al. Development of a neutralization assay for Nipah virus using pseudotype particles. J. Virol. Methods. 2009;160:1&#x2013;6. doi: 10.1016/j.jviromet.2009.02.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2009.02.025</ArticleId><ArticleId IdType="pmc">PMC2704486</ArticleId><ArticleId IdType="pubmed">19559943</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W, et al. Establishment of retroviral pseudotypes with influenza hemagglutinins from H1, H3, and H5 subtypes for sensitive and specific detection of neutralizing antibodies. J. Virol. Methods. 2008;153:111&#x2013;119. doi: 10.1016/j.jviromet.2008.07.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2008.07.015</ArticleId><ArticleId IdType="pubmed">18722473</ArticleId></ArticleIdList></Reference><Reference><Citation>Zettl F, et al. Rapid quantification of SARS-CoV-2-neutralizing antibodies using propagation-defective vesicular stomatitis virus pseudotypes. Vaccines (Basel) 2020 doi: 10.3390/vaccines8030386.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines8030386</ArticleId><ArticleId IdType="pmc">PMC7563800</ArticleId><ArticleId IdType="pubmed">32679691</ArticleId></ArticleIdList></Reference><Reference><Citation>Cussler E. Difussion. 3. Cambridge University Press; 2009. pp. 117&#x2013;160.</Citation></Reference><Reference><Citation>Vidor, E. Poliovirus vaccine-inactivated. In Plotkin's Vaccines Edtsevebth edn (eds Plotkin, S. A et al.) 858 (Elsevier, 2018) doi:10.1016/C2013-0-18914-3.</Citation></Reference><Reference><Citation>Reinheimer C, Friedrichs I, Rabenau HF, Doerr HW. Deficiency of immunity to poliovirus type 3: A lurking danger? BMC Infect. Dis. 2012;12:24. doi: 10.1186/1471-2334-12-24.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2334-12-24</ArticleId><ArticleId IdType="pmc">PMC3298481</ArticleId><ArticleId IdType="pubmed">22280025</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO. https://polioeradication.org/news-post/global-eradication-of-wild-poliovirus-type-2-declared/. (2015).</Citation></Reference><Reference><Citation>WHO. https://www.who.int/news-room/feature-stories/detail/two-out-of-three-wild-poliovirus-strains-eradicated. (2019).</Citation></Reference><Reference><Citation>Drexler JF, et al. Robustness against serum neutralization of a poliovirus type 1 from a lethal epidemic of poliomyelitis in the Republic of Congo in 2010. Proc. Natl. Acad. Sci. USA. 2014;111:12889&#x2013;12894. doi: 10.1073/pnas.1323502111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1323502111</ArticleId><ArticleId IdType="pmc">PMC4156724</ArticleId><ArticleId IdType="pubmed">25136105</ArticleId></ArticleIdList></Reference><Reference><Citation>Alam MM, et al. Antigenic structure of wild poliovirus type 1 strains endemic in Pakistan is highly conserved and completely neutralized by Sabin's Oral Polio Vaccine. J. Infect. Dis. 2021 doi: 10.1093/infdis/jiab555.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab555</ArticleId><ArticleId IdType="pubmed">34791319</ArticleId></ArticleIdList></Reference><Reference><Citation>Diamond DC, et al. Antigenic variation and resistance to neutralization in poliovirus type 1. Science. 1985;229:1090&#x2013;1093. doi: 10.1126/science.2412292.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.2412292</ArticleId><ArticleId IdType="pubmed">2412292</ArticleId></ArticleIdList></Reference><Reference><Citation>Blondel B, et al. Mutations conferring resistance to neutralization with monoclonal antibodies in type 1 poliovirus can be located outside or inside the antibody-binding site. J. Virol. 1986;57:81&#x2013;90. doi: 10.1128/jvi.57.1.81-90.1986.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.57.1.81-90.1986</ArticleId><ArticleId IdType="pmc">PMC252701</ArticleId><ArticleId IdType="pubmed">2416957</ArticleId></ArticleIdList></Reference><Reference><Citation>Hara M, Hagiwara A, Yoneyama T, Saito Y, Shimojo H. Antigenic and biochemical characterization of poliovirus type 1 isolates of non-vaccine origin. Microbiol. Immunol. 1983;27:1057&#x2013;1065. doi: 10.1111/j.1348-0421.1983.tb02939.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1348-0421.1983.tb02939.x</ArticleId><ArticleId IdType="pubmed">6328228</ArticleId></ArticleIdList></Reference><Reference><Citation>Knowlson S, et al. New strains intended for the production of inactivated polio vaccine at low-containment after eradication. PLoS Pathog. 2015;11:e1005316. doi: 10.1371/journal.ppat.1005316.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1005316</ArticleId><ArticleId IdType="pmc">PMC4699825</ArticleId><ArticleId IdType="pubmed">26720150</ArticleId></ArticleIdList></Reference><Reference><Citation>Farcet MR, et al. Continued use of poliovirus after eradication: hyper-attenuated strains as a safe alternative for release testing of human immunoglobulins. Transfusion. 2018;58(Suppl 3):3084&#x2013;3089. doi: 10.1111/trf.15048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/trf.15048</ArticleId><ArticleId IdType="pubmed">30536436</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization . Manual of Laboratory Methods for Potency Testing of Vaccines Used in the WHO Expanded Programme on Immunization. WHO Publication No. WHO/BLG/95.1. World Health Organization; 1995. p. 1995.</Citation></Reference><Reference><Citation>Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2013;48:452&#x2013;458. doi: 10.1038/bmt.2012.244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/bmt.2012.244</ArticleId><ArticleId IdType="pmc">PMC3590441</ArticleId><ArticleId IdType="pubmed">23208313</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>